Spots Global Cancer Trial Database for Evaluation of Protein in the Urine in Patients Receiving Bevacizumab
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Evaluation of Protein in the Urine in Patients Receiving Bevacizumab
Official Title: An Evaluation of Proteinuria in Patients Receiving Shortened Infusions of Bevacizumab
Study ID: NCT00849394
Interventions
Study Description
Brief Summary: This is a clinical research study to look at the incidence of proteinuria (a condition in which urine contains an abnormal amount of protein) caused by shortened infusions (given into the vein over 10 or 15 minutes) of bevacizumab (a medication prescribed for colon, lung, or breast cancer). There are currently no published studies or clinical data looking at how safe shortened infusions of bevacizumab are in relationship to the side effect of proteinuria. We hypothesis that shortened infusions of bevacizumab will result in an increased risk for proteinuria compared to the standard infusions of this agent.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
VA North Texas Health Care System, Dallas, Texas, United States
Parkland Health and Hospital System, Dallas, Texas, United States
UT Southwestern Medical Center, Dallas, Texas, United States
Contact Details
Name: Sachin Shah, Pharm.D.
Affiliation: Texas Tech University Health Sciences Center School of Pharmacy
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
